Scarica l'app Stockscreener
3.27
5.22%
-0.18
Dopo l'orario di chiusura:
3.27
Precedente Chiudi:
$3.45
Aprire:
$3.45
Volume 24 ore:
412.05K
Relative Volume:
0.32
Capitalizzazione di mercato:
$117.53M
Reddito:
-
Utile/perdita netta:
$-35.17M
Rapporto P/E:
-2.8086
EPS:
-1.1643
Flusso di cassa netto:
$-29.83M
1 W Prestazione:
-9.42%
1M Prestazione:
+202.78%
6M Prestazione:
+155.47%
1 anno Prestazione:
+133.57%
Intervallo 1D:
$3.11
$3.536
Intervallo di 1 settimana:
$3.11
$4.01
Portata 52W:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Nome
An 2 Therapeutics Inc
Settore
Industria
Telefono
(650) 331-9090
Indirizzo
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
3.27 | 117.53M | 0 | -35.17M | -29.83M | -1.1643 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Mostra tutto
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 - quiverquant.com
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - Finviz
Viking Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - MarketScreener
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Denali Therapeutics Inc.: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - FinanzNachrichten.de
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - stocktitan.net
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1Slideshow (NASDAQ:GPCR) 2026-03-16 - Seeking Alpha
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - PR Newswire
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - BioSpace
Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - BioSpace
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
HIT trial: CAD-1005 patients had 50% clot rate vs >75% on placebo - Stock Titan
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewswire
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
Allarity Therapeutics Doses First Patients in VA-Funded - globenewswire.com
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
Cyclerion Therapeutics Announces Progress Toward CYC-126 - globenewswire.com
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - GlobeNewswire
Assessing Structure Therapeutics (GPCR) Valuation As GSBR-1290 Advances Through Phase 2 Obesity Trials - Yahoo Finance
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewswire
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer - Business Wire
Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics
FDA lets Intellia resume MAGNITUDE-2 Phase 3 trial for ATTRv-PN - Stock Titan
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in - GlobeNewswire
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Cancer imaging company buys Lisata for phase 2-stage solid tumor drug - Fierce Biotech
GSK enters agreement to acquire RAPT Therapeutics - GSK
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 - BioSpace
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia - PR Newswire
An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):